Perioperative adjuvant treatment and complete resection is the standard treatment for
resectable pancreatic cancer and systemic chemotherapy is standard treatment for …

Pancreatic cancer (PDAC) is one of the most aggressive solid tumors and is showing
increasing incidence. The aim of our review is to provide practical help for all clinical …

Background Liver oligometastatic pancreatic cancer (PC) may have favorable outcomes.
This study aims to evaluate outcomes and factors associated with overall survival (OS) of …

Background The efficacy of modified FOLFIRINOX (mFOLFIRINOX) as a second-line
chemotherapy treatment for metastatic pancreatic adenocarcinoma (mPAC), remains …

In this study, we evaluated the association of modified Glasgow Prognostic Score (mGPS)
with prognosis in pancreatic cancer (PC) by performing a meta-analysis. Potentially eligible …

A combination of chemotherapy with immunotherapy has been proposed to have better
clinical outcomes in Pancreatic Ductal Adenocarcinoma (PDAC). On the other hand …

In spite of recent diagnostic and therapeutic advances, the prognosis of pancreatic ductal
adenocarcinoma (PDAC) remains very poor. As most patients are not amenable to curative …

Globally, the death rate of pancreatic ductal adenocarcinoma (PDAC) has doubled over 30
years and is likely to further increase, making PDAC a leading cause of cancer-related death …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is a common type of cancer
originating from the pancreatic glands and is characterized by a rapidly progressive course …

Gemcitabine (GEM) and its derivatives of deoxycytosine is a promising anticancer candidate
which is effective for the treatment of various cancers including lung cancer via cascade …